Hopp til innhold
NHI.no
Annonse

Hudlymfom (mycosis fungoides): Årsaker

Sykdommen kommer av at unormale T-lymfocytter beveger seg til huden, der de etter hvert utvikler seg til kreftceller. Mikrober, yrkesmessig eksponering og endringer i arvematerialet (genetiske mutasjoner) har vært vurdert som årsaksfaktorer, men sikker dokumentasjon foreligger ikke. Det finnes mange ulike varianter av hudlymfom.

Annonse

Dette dokumentet er basert på det profesjonelle dokumentet Kutant T-cellelymfom (Mycosis fungoides) . Referanselisten for dette dokumentet vises nedenfor

  1. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne lymfomer, 2019. www.helsebiblioteket.no
  2. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350: 1978-88. PubMed
  3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127(20):2375-90. Blood
  4. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011;29:2598-2607. PubMed
  5. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005 May 15. 105(10):3768-85.
  6. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007;143:854-859. PubMed
  7. Herne KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome. Blood 2003; 101: 2132-2136. Blood
  8. Herne KL, Talpur R, Breuer-McHam J, et al. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome. Blood 2003;101:2132-2135. Blood
  9. Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 2019; 181: 350-7. pmid:30267549 PubMed
  10. Sezary A, Bouvrain Y. Erythrodermie avec presence de cellules monstrueses dans le derme and dans lang circulant. Bull Soc Fr Dermatol Syph 1938; 45: 254. PubMed
  11. Willemze R. Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg 2018; 37:11. PubMed
  12. Liu V, McKee PH. Cutaneous T-cell lymphoproliferative disorders: approach for the surgical pathologist: recent advances and clarification of confused issues. Adv Anat Pathol 2002; 9: 79-100. PubMed
  13. Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003; 102: 2213-19. Blood
  14. Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas: report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003;97:610-627. PubMed
  15. Weberschock T, Strametz R, Lorenz M, et al. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2012;(9):CD008946. Cochrane (DOI)
  16. Trautinger F1, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014-30. pmid:16574401 PubMed
  17. Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011 Feb. 64(2):352-404.
  18. Specht L, Dabaja B, Illidge T, et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015; 92:32. PubMed
Annonse
Annonse